EyePoint, Inc. · NASDAQ:EYPT

EyePoint — EyePoint Pharmaceuticals — 24th Euretina Congress 2024

18 slides from EyePoint's conference presentation, Sep 19, 2024

  1. Slide 1: Subgroup Analysis from the DAVIO 2 Trial of EYP-1901 in Wet AMD

    Subgroup Analysis from the DAVIO 2 Trial, a Phase 2, Multicenter Study of a Single Injection of EYP-1901 (Vorolanib Intravitreal Insert) vs Aflibercept for Previously Treated Wet Age-Related Macular Degeneration Giovanni Staurenghi1 on behalf of DAVIO 2 investigators and coauthors David A. Eichenbau

  2. Slide 2: Presenter Disclosures

    Presenter Disclosures Consultant/Advisor: Abbvie, Apellis, Annexon, Bayer, Boehringer Ingelheim, Centervue, Genentech, Heidelberg Engineering, Iveric, Medscape, Nidek, Novartis, Optos, ORA, RetinAI, Roche; Lecture Fees/Speakers Bureau: Carl Zeiss Meditec, Centervue, Heidelberg Engineering, Medscape,

  3. Slide 3: EYP-1901 (DURAVYU): Vorolanib in Durasert E

    EYP-1901 (DURAVYUTM [vorolanib intravitreal insert]): Vorolanib in Durasert ETM EYP-1901 Vorolanib Durasert E Controlled release over a Potent receptor tyrosine kinase Bioerodible, sustained period of at least 6 months inhibitor (TKI): selectively inhibits all IVT drug delivery VEGF signaling No del

  4. Slide 4: DAVIO 2: Phase 2 trial of EYP-1901 vs aflibercept in previously-treated wet AMD

    DAVIO 2: Phase 2 trial of EYP-1901 vs aflibercept in previously-treated wet AMD Primary endpoint EYP-1901 dosing Blend W28 & W32 Key Inclusion & 161 patients W36 to D1 W4 W8 W12 W16 W20 W24 W28 W32 Exclusion Criteria W56 EYP-1901 2 mg low dose • Diagnosed with wAMD at any time (n = 53) • History of

  5. Slide 5: Baseline characteristics well balanced across arms

    Baseline characteristics well balanced across arms Aflibercept 2 mg q8W EYP-1901 2 mg EYP-1901 3 mg (n = 54) (n = 50) (n = 52) Baseline Characteristics (N = 156) Age, mean years (range) 76 (52–93) 76 (61–93) 75 (56–89) Female, % 54% 64% 67% BCVA, mean ETDRS letter score (range) 73.4 (41–85) 73.9 (52

  6. Slide 6: DAVIO 2 EYP-1901 maintained vision and CST; well-tolerated

    DAVIO 2 EYP-1901 maintained vision and CST Week 32 EYP-1901 well-tolerated with an acceptable safety profile Primary endpoint Mean BCVA change M7/8 averaged 10 Key Safety Findings BCVA change from baseline, mean ± SD ETDRS letters 5 • No reported ocular 0 SAEs, systemic SAEs, or discontinuations -5

  7. Slide 7: Two-thirds of eyes receiving EYP-1901 were supplemental injection-free up to Month 8

    Two-thirds of eyes receiving EYP-1901 were supplemental injection–free up to Month 8 EYP-1901 dosing Patients received aflibercept every 8 weeks 100% 100% 98% 96% 100% Eyes supplemental injection–free 88% 87% up to specified week, %a 100% 98% 79% 80% 100% 87% 63% 98% 60% 75% 74% 84% 63% 70% 40% 20%

  8. Slide 8: Eyes with supplemental injections did not drive BCVA outcomes

    Eyes with supplemental injections did not drive BCVA outcomes Mean BCVA Change, All Eyes 10 Months 7/8 averaged BCVA change from baseline, 5 Aflibercept 2 mg q8W +1.3 ETDRS letters (n = 54) EYP-1901 2 mg 0 +1.0 (n = 50) EYP-1901 3 mg +0.9 -5 (n = 52) -10 Mean BCVA Change, Eyes Without Supplemental T

  9. Slide 9: Eyes with supplemental injections did not drive anatomical outcomes

    Eyes with supplemental injections did not drive anatomical outcomes Mean CST Change, All Eyes 75 Month 8 CST change from baseline, 50 Aflibercept 2 mg q8W 25 +5.4 (n = 54) EYP-1901 2 mg +17.8 µm 0 (n = 50) -25 EYP-1901 3 mg +10.6 (n = 52) -50 -75 Mean CST Change, Eyes Without Supplemental Treatmenta

  10. Slide 10: Baseline BCVA had no meaningful impact on BCVA outcomes

    Baseline BCVA had no meaningful impact on BCVA outcomes Mean BCVA Change, Baseline BCVA < 75 ETDRS Letters 10 Months 7/8 averaged BCVA change from baseline, 5 Aflibercept 2 mg q8W +1.9 ETDRS letters (n = 23) EYP-1901 2 mg 0 +1.4 (n = 20) EYP-1901 3 mg +2.6 -5 (n = 22) -10 Mean BCVA Change, Baseline

  11. Slide 11: Baseline BCVA had no meaningful impact on CST outcomes

    Baseline BCVA had no meaningful impact on CST outcomes Mean CST Change, Baseline BCVA < 75 ETDRS Letters 75 Month 8 CST change from baseline, 50 Aflibercept 2 mg q8W 25 −3.2 (n = 23) EYP-1901 2 mg +16.8 µm 0 (n = 20) -25 EYP-1901 3 mg +13.1 (n = 22) -50 -75 Mean CST Change, Baseline BCVA ≥ 75 ETDRS

  12. Slide 12: Duration of wAMD diagnosis had no meaningful impact on BCVA outcomes

    Duration of wAMD diagnosis had no meaningful impact on BCVA outcomes Mean BCVA Change, Diagnosed < 12 Months 10 Months 7/8 averaged BCVA change from baseline, 5 Aflibercept 2 mg q8W +1.8 ETDRS letters (n = 25) EYP-1901 2 mg 0 −0.5 (n = 18) EYP-1901 3 mg +0.8 -5 (n = 24) -10 Mean BCVA Change, Diagnos

  13. Slide 13: Duration of wAMD diagnosis had no meaningful impact on CST outcomes

    Duration of wAMD diagnosis had no meaningful impact on CST outcomes Mean CST Change, Diagnosed < 12 Months 75 Month 8 CST change from baseline, 50 Aflibercept 2 mg q8W 25 +3.6 (n = 25) EYP-1901 2 mg +9.5 µm 0 (n = 18) -25 EYP-1901 3 mg +17.7 (n = 24) -50 -75 Mean CST Change, Diagnosed ≥ 12 Months 75

  14. Slide 14: Comparison of number of historical anti-VEGF injections on BCVA outcomes

    Comparison of number of historical anti-VEGF injections on BCVA outcomes Mean BCVA Change, 10 ≤ 5 Historical Anti-VEGF Injections During Prior 12 Months Months 7/8 averaged BCVA change from baseline, 5 Aflibercept 2 mg q8W +4.0 ETDRS letters (n = 26) EYP-1901 2 mg 0 −0.5 (n = 19) EYP-1901 3 mg +1.5

  15. Slide 15: Historical anti-VEGF injections on CST outcomes; no sawtooth pattern

    Comparison of number of historical anti-VEGF injections on CST outcomes; No sawtooth pattern in eyes receiving EYP-1901 Mean CST Change, 75 ≤ 5 Historical Anti-VEGF Injections During Prior 12 Months Month 8 CST change from baseline, 50 Aflibercept 2 mg q8W 25 +1.2 (n = 26) EYP-1901 2 mg +6.0 µm 0 (n

  16. Slide 16: Nearly identical BCVA change with EYP-1901 and aflibercept at 12 months

    DAVIO 2 | 1 year Nearly identical BCVA change with EYP-1901 and aflibercept at 12 months 15 EYP-1901 dosing Expected minimum duration of EYP-1901 In humans 10 Mean change vs BCVA change from baseline, aflibercept q8W mean ± SD ETDRS letters 5 Aflibercept q8W −0.5 0 EYP-1901 2 mg −0.1 +0.4 letters EY

  17. Slide 17: DAVIO 2 trial subgroup data supports durability of EYP-1901 up to 6 months

    DAVIO 2 trial subgroup data supports durability of EYP-1901 up to 6 months • DAVIO 2 is the largest IVT TKI trial to date • EYP-1901 maintained stable visual acuity with strong anatomical control over 32 weeks • Eyes without supplemental injections did just as well as all eyes suggesting that supple

  18. Slide 18: EYP-1901 in wet AMD: Phase 3 pivotal trial design

    EYP-1901 in wet AMD: Phase 3 pivotal trial design LUGANO & LUCIA: Patients with wet AMD, previously-treated or treatment-naïve Primary endpoint Blend W52 & W56 EYP-1901 dosing EYP-1901 dosing EYP-1901 dosing W60 to W84 to W96 D1 W4 W8 W12 W16 W20 W24 W28 W32 W36 W40 W44 W48 W52 W56 W80 W76 W92 EOS E

EyePoint Pharmaceuticals — 24th Euretina Congress 2024 on 6ix